Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers
Yahoo · 15 de oct de 2026
This deal sees Gilead double down on TCEs, following its first bet on the modality through its March buyout of autoimmune-focused Ouro Medicines.
CEDEAR GILD
Gilead Sciences, Inc.
Sí, existe CEDEAR de GILD en Argentina. Operás bajo el ticker GILD en BYMA, con ratio 4:1 respecto a la acción en NASDAQ.
Empresa subyacente
HealthcareDrug Manufacturers - General
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.
- País
- United States
- Empleados
- 17.000
- Sitio web
- gilead.com
Precio histórico
Últimos 223 días · 12/11/25 — 13/10/26
+31.00%
Cotización y datos
NASDAQRatio 4:1 · Subyacente GILD
CEDEAR (ARS)
Precio
$ 64.450
Var. %
+4,03%
Volumen operado
251
Subyacente (USD)
Precio GILD
US$ 159,27
Teórico (precio / ratio)
GILD ÷ 4
US$ 39,82
Dólar MEP (GILDD)
Preguntas frecuentes
¿Existe CEDEAR de GILD en Argentina?
Sí, existe el CEDEAR de GILD (Gilead Sciences, Inc.) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es GILD.
¿Cuál es el ticker del CEDEAR de Gilead Sciences, Inc.?
El ticker del CEDEAR de Gilead Sciences, Inc. en Argentina es GILD. La acción subyacente cotiza en NASDAQ con el símbolo GILD.
¿Cuál es el ratio del CEDEAR GILD?
El CEDEAR GILD tiene un ratio de 4:1. Eso significa que 4 CEDEARs equivalen a 1 acción de GILD.
¿Cuánto vale el CEDEAR GILD hoy?
El CEDEAR GILD cotiza hoy a $ 64.450 en pesos argentinos, con una variación diaria de +4,03%.
¿Cuánto vale la acción GILD en dólares?
Noticias
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Yahoo · 15 de oct de 2026
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Top S&P500 movers in Wednesday's session
ChartMill · 14 de oct de 2026
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.
